Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Urothelial Cancer: early-phase trial registry
12 of 26 indexed Urothelial Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #627 of 28,707 conditions by registered trial count.
26 US clinical trials · 12 currently recruiting · #627 of 28,707 conditions by registered trial count
Urothelial Cancer: 26 US clinical trials tracked, 12 recruiting.
Urothelial Cancer is the subject of 26 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition urothelial-cancer
OPEN 12 | RECR 46% | LATE 6 | EARLY 16 | RANK #627 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Biphenotypic Leukemia (46% recruiting · 13 trials)
Urothelial Cancer lists 12 open slots (46% of 26 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Urothelial Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Urothelial Cancer is recruiting above its size-band peers.
12 of 26 indexed trials (46.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Urothelial Cancer trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 3 of 26 trials (11.5%). 19 distinct sponsors appear on at least one study for this condition label.
-
Typical Urothelial Cancer enrolment sits around 355 participants.
Median target enrolment is 355 among the 26 trials that report a genuine target (sentinel values excluded). 3 of those (11.5%) plan for fewer than 100 participants.
-
Urothelial Cancer research is mostly interventional.
22 interventional and 4 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
26 total, page 1 of 1
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
National Cancer Institute (NCI)
NCT04923178
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
NCT07129993
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Lahey Clinic
NCT00872495
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
National Cancer Institute (NCI)
NCT02379429
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
NCT07106762
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
NCT05489211
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics
NCT07193511
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Sacituzumab Govitecan Plus EV in Metastatic UC
Dana-Farber Cancer Institute
NCT04724018
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Cancer Institute (NCI)
NCT04235777
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Dan Zandberg
NCT04114136
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NCT06771219
A Genotype-Phenotype Urothelial Cancer Registry
Memorial Sloan Kettering Cancer Center
NCT00902590
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Bristol-Myers Squibb
NCT03036098
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
AstraZeneca
NCT02516241
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Astellas Pharma Global Development
NCT04223856
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Janssen Research & Development
NCT03390504
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Astellas Pharma Global Development
NCT03288545
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
BicycleTx Limited
NCT04180371
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Janssen Research & Development
NCT02365597
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
Hoffmann-La Roche
NCT05645692
A Study of ADRX-0706 in Select Advanced Solid Tumors
Adcentrx Therapeutics
NCT06036121
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Uswm CT
NCT04044859
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Pfizer
NCT05059522
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Pfizer
NCT02603432
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Astellas Pharma
NCT03219333
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 7 |
| Phase 3 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Urothelial Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Urothelial Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Urothelial Cancer page
26 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Urothelial Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Urothelial Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urothelial Cancer condition card totals 26 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.